CVSI · CV Sciences, Inc.
$0.02
+0.00 (+2.50%)
At close · Jul 29
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company's financial operating results and accumulated deficit, amongst other factors, raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$3.88M
Shares
203.98M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$13.79M
-12.2%
FY2025
Net Income
-$958K
+60%
FY2025
Gross Margin
48.97%
+3.3pp
FY2025
Operating Margin
-3.41%
+10.5pp
FY2025
Diluted EPS
-$0.01
0%
FY2025
Operating Cash Flow
-$407K
+52.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $13.38M | $13.79M | $15.71M | $16M | $16.21M | $20.05M | $24.43M | $53.7M | $48.24M | $20.68M | $11.06M | $11.53M | $10.19M | $2.15M | $0 | — | |
| -$895K | — | — | — | -$1.54M | -$140K | -$9000 | $15K | -$153K | — | — | — | — | — | — | — | |
| $6.72M | $7.04M | $8.54M | $8.92M | $10.66M | $11.43M | $13.42M | $18.61M | $14.37M | $6.19M | $4.06M | $4.8M | $4.39M | $880.47K | $0 | — | |
| $6.66M | $6.75M | $7.17M | $7.09M | $5.55M | $8.62M | $11.01M | $35.09M | $33.88M | $14.49M | $7M | $6.73M | $5.8M | $1.27M | $0 | — | |
| — | 48.97% | 45.64% | 44.27% | 34.25% | 42.98% | 45.07% | 65.35% | 70.22% | 70.07% | 63.27% | 58.38% | 56.95% | 59.13% | — | — | |
| $110K | $122K | $118K | $151K | $307K | $1.19M | $2.94M | $5.88M | $1.89M | $724K | $1.16M | $1.32M | $999.28K | $524.48K | $0 | — | |
| $2.98M | $3.15M | $3.99M | $3.74M | $12.09M | $25.88M | $30.66M | $46.45M | $21.75M | $16.19M | $13.13M | $17.38M | $13.36M | $2.37M | $43.02K | $96.52K | |
| $7.35M | $7.62M | $9.24M | $9.75M | $12.09M | $25.88M | $30.66M | $46.45M | $21.75M | $16.19M | $13.13M | $17.38M | — | — | $139.54K | $88.09K | |
| — | $24K | $21K | $1000 | — | — | — | — | — | — | — | — | $821.5K | $753.5K | — | — | |
| — | $192K | $334K | $235K | $992K | $1.15M | $872K | $716K | $519K | $183K | $1.05M | $1.01M | $933.6K | $767.25K | $0 | — | |
| — | — | — | — | $12.4M | $27.06M | $33.6M | $52.33M | $23.63M | $19.35M | $20.07M | $18.7M | $14.36M | $2.89M | $43.02K | $88.09K | |
| -$799K | -$470K | -$2.19M | $3.36M | -$6.85M | -$18.45M | -$22.59M | -$17.24M | $10.25M | -$4.86M | -$13.07M | -$11.21M | -$8.55M | -$1.62M | -$43.02K | — | |
| — | -3.41% | -13.94% | 20.99% | -42.25% | -92.01% | -92.48% | -32.11% | 21.24% | -23.5% | -118.2% | -97.23% | -83.93% | -75.08% | — | — | |
| — | -$278K | -$1.86M | $3.6M | -$5.86M | -$17.29M | -$21.72M | -$16.52M | $10.77M | -$4.68M | -$12.02M | -$10.2M | -$7.62M | -$850.08K | -$43.02K | — | |
| — | $517K | $212K | — | — | — | — | — | $153K | $507K | $1.09M | $968.62K | $615.34K | $372.11K | $2593 | $2088 | |
| — | -$479K | -$212K | -$264K | -$1.54M | — | — | — | -$153K | -$519K | -$1.07M | -$1.02M | $7.24M | -$682.86K | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | $0 | -$38.55K | -$310.75K | $0 | — | |
| -$1.49M | -$949K | -$2.4M | $3.1M | -$8.26M | -$15.64M | -$22.6M | -$17.23M | $10.09M | -$5.38M | -$14.14M | -$12.23M | — | — | — | — | |
| $2000 | $9000 | -$8000 | -$6000 | -$47K | -$87K | -$317K | -$615K | $93K | -$482K | $0 | $0 | $0 | $0 | $0 | — | |
| -$1.49M | -$958K | -$2.39M | $3.1M | -$8.21M | -$15.55M | -$22.28M | -$16.61M | $10M | -$4.9M | -$14.14M | -$12.23M | -$1.31M | -$2.3M | -$45.61K | -$90.18K | |
| — | -6.95% | -15.24% | 19.38% | -50.69% | -77.58% | -91.22% | -30.93% | 20.73% | -23.68% | -127.85% | -106.1% | -12.87% | -106.78% | — | — | |
| — | — | -$2.39M | $3.1M | -$9.13M | -$15.55M | — | — | — | — | — | — | — | — | — | — | |
| -$1.47M | -$884K | -$2.42M | $3.11M | -$8.21M | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$0.01 | -$0.01 | $0.02 | -$0.07 | -$0.14 | -$0.22 | -$0.17 | $0.11 | -$0.06 | — | -$0.35 | -$0.04 | -$0.23 | — | — |
| USD/shares | — | -$0.01 | -$0.01 | $0.02 | -$0.07 | -$0.14 | -$0.22 | -$0.17 | $0.09 | -$0.06 | — | — | — | — | — | — |
| shares | — | 184.26M | 175.59M | 153.95M | 138.03M | 107.82M | 99.91M | 97.86M | 91.92M | 80.43M | 52.66M | 35.14M | 31.58M | 9.88M | 7M | 6.97M |
| shares | — | 184.26M | 175.59M | 153.96M | 138.03M | 107.82M | 99.91M | 97.86M | 114.47M | 80.43M | 52.66M | 35.14M | — | 9.88M | 7M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 0.45×
EV/EBIT
—
P/E (TTM)
—
Peer median 27.12×
Peer medians compare against the 27 similar-size Drug Manufacturers - Specialty & Generic companies (of 91 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| Consumer Products | $20,048,000 | $24,429,000 | $53,696,000 |
| Specialty Pharmaceuticals | $0 | $0 | $0 |
By Product & Service (USD)
| Component | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Shipping And Handling | $100,000 | $100,000 | $200,000 | $300,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| Specialty Pharmaceuticals | -$5,787,000 | -$2,376,000 | -$3,817,000 |
| Consumer Products | -$12,659,000 | -$20,216,000 | -$13,423,000 |
Operating Margin by Segment (%)
| Component | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| Consumer Products | -63.1% | -82.8% | -25% |